IGF::OT::IGF SBIR PHASE I TOPIC 331: OPTICAL BIOSENSOR FOR REAL-TIME ASSESSMENT OF TUMOR CELLULARITY DURING CORE NEEDLE BIOPSY

IGF::OT::IGF SBIR 第一阶段主题 331：用于芯针活检期间实时评估肿瘤细胞性的光学生物传感器

• 批准号: 8945534
• 负责人: NICUSOR IFTIMIA
• 金额: $ 23万
• 依托单位: PHYSICAL SCIENCES, INC
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-22 至 2015-06-21
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8945534
• 关键词: Address; Algorithms; Animal Cancer Model; Animal Model; Animals; Area; Biochemical; Biopsy; Biosensor; Boston; Breast; Caliber; Cancer Center; Cancer Model; Cellularity; Collaborations; Collection; Computer software; Core Biopsy; Data; Data Collection; Devices; Discrimination; Feedback; Fibrosis; Guns; Heterogeneity; Histocompatibility Testing; Hour; Human Resources; IACUC; Inflammation; Institutional Review Boards; Lateral; Liver; Location; Lung; Malignant Neoplasms; Modality; Morphology; Necrosis; Needle biopsy procedure; Operative Surgical Procedures; Optics; Ovarian Tissue; Pathology; Patients; Performance; Phase; Physicians; Procedures; Process; Protocols documentation; Resolution; Safety; Sampling; Scanning; Sensitivity and Specificity; Signal Transduction; Site; Small Business Innovation Research Grant; Specimen; Technology; Testing; Time; Tissues; Training; Tumor Tissue; Ultrasonography; United States National Institutes of Health; animal facility; computerized data processing; data acquisition; design; graphical user interface; human tissue; imaging probe; in vivo; instrument; instrumentation; interest; malignant breast neoplasm; meetings; new technology; physical science; programs; skills; success; tumor

Physical Sciences, Inc. (PSI), in collaboration with MD Anderson Cancer Center, will develop and test a novel technology for real-time assessment of tumor cellularity during core needle biopsy procedures. This technology will address one of the main issues that physicians encounter when performing biopsies: inability of collecting sufficient or adequate material for histological analysis due to tumor heterogeneity (mixture of viable tumor, necrosis, fibrosis and inflammation). As a result, biopsy success ranges from 70 to 95%, depending on the physician skills, tumor size, and biopsy location. Unfortunately, even when guided by ultrasound or CT, tumor cellularity remains an issue due to lack of resolution of these imagining modalities which cannot distinguish with certainty what areas of a mass contain viable tumor tissue. To address this problem PSI will aid the biopsy process by providing real-time tumor cellularity data captured by an optical biosensor which will investigate the morphology and the biochemical signature of the investigated mass, such that high tumor content regions can be reliably detected. The technology will be first tested ex vivo on tissue specimens and then its suitability for in vivo use will be tested on an animal model of cancer.

物理科学公司(PSI)与MD安德森癌症中心合作，将开发和测试一种新技术，用于在芯针活检过程中实时评估肿瘤细胞结构。该技术将解决医生在进行活检时遇到的主要问题之一：由于肿瘤异质性（活肿瘤、坏死、纤维化和炎症的混合物），无法收集足够或足够的材料进行组织学分析。因此，活检成功率为70%至95%，取决于医生的技能，肿瘤大小和活检位置。不幸的是，即使在超声或CT引导下，由于这些成像模式的分辨率不足，肿瘤细胞构成仍然是一个问题，这些成像模式不能确定地区分肿块的哪些区域包含有活力的肿瘤组织。为了解决这个问题，PSI将通过提供由光学生物传感器捕获的实时肿瘤细胞数数据来帮助活检过程，该光学生物传感器将研究所研究的质量的形态和生化特征，使得可以可靠地检测高肿瘤含量区域。该技术将首先在组织标本上进行体外测试，然后在癌症动物模型上测试其体内使用的适用性。